RARA and acute promyelocytic leukemia: In addition, we examined only APL cases with PML-RARA fusion, but RARA may have other fusion partners, such as ZBTB16, NUMA1, STAT5B, or NPM1. The variant fusion partner is important because it can influence the prognosis through the response to ATRA.